Status:
COMPLETED
Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
18-99 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.
Eligibility Criteria
Inclusion
- Malignant solid tumor for which there is no currently approved treatment
- Adequate bone marrow, liver, cardiac, and kidney function
Exclusion
- Cardiac disease
- Anticancer therapy within 4-6 weeks (depending on therapy)
- Pregnant or breast-feeding
Key Trial Info
Start Date :
October 11 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2010
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00225121
Start Date
October 11 2005
End Date
September 23 2010
Last Update
December 21 2018
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States, 90095
2
UCLA Hematology/Oncology
Los Angeles, California, United States, 90095
3
UCLA Oncology Center
Los Angeles, California, United States, 90095
4
UCLA Hematology Oncology - Santa Monica
Santa Monica, California, United States, 90404